<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339844</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2013-149</org_study_id>
    <nct_id>NCT02339844</nct_id>
  </id_info>
  <brief_title>Pan European Collaboration on Antipsychotic Naïve Schizophrenia II</brief_title>
  <acronym>PECANSII</acronym>
  <official_title>Pan European Collaboration on Antipsychotic Naïve Schizophrenia II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective 2 year multimodal follow-up study of initially antipsychotic-naïve&#xD;
      first-episode psychotic patients involving a standardized intervention with monotherapy with&#xD;
      aripiprazole during the first 6 weeks. Patients and matched healthy controls will be examined&#xD;
      after 6 weeks, 6 months and 2 years. They will be examined with MR-scannings, neurocognitive&#xD;
      tests, EEG, and PET-scannings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective 2 year multimodal follow-up study of initially antipsychotic-naïve&#xD;
      first-episode psychotic patients involving a standardized intervention with monotherapy with&#xD;
      aripiprazole during the first 6 weeks. Patients and matched healthy controls will be examined&#xD;
      at baseline and after 6 weeks, 6 months and 2 years.&#xD;
&#xD;
      Levels of glutamate and gamma-aminobutyric acid (GABA) are measured by proton magnetic&#xD;
      resonance spectroscopy (1H-MRS) in the anterior cingulate cortex ACC and thalamus.&#xD;
      Presynaptic Dopamine level is measured with Positron Emission Tomography Computed Tomography&#xD;
      (PET/CT)-scanning using 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA). Disturbances&#xD;
      of the reward system is measured with functional magnetic resonance imaging (fMRI) . Regional&#xD;
      cerebral blood flow and activity in the same regions are measured with Pseudo-continuous&#xD;
      arterial spin labelling (pCASL). The default mode network, functional and structural&#xD;
      connectivity in the associated macro circuits are measured with resting state fMRI, EEG, and&#xD;
      diffusion tensor imaging. Structural brain changes (in grey and white matter) are measured&#xD;
      with MRI. Cognitive functions are measured with a neuropsychological test battery, and early&#xD;
      information processing with event related EEG and electromyography (EMG) (psychophysiological&#xD;
      examinations). Further patients psychopathology will be rated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutamate level in Anterior Cingulate Cortex (measured with magnetic resonance spectroscopy)</measure>
    <time_frame>Baseline, 6 weeks, 6 months, 2 years</time_frame>
    <description>Glutamate level at baseline and change over time as measured with magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness (measured with magnetic resonance and free surfer)</measure>
    <time_frame>Baseline, 6 weeks, 6 months &amp; 2 years</time_frame>
    <description>Thickness of grey matter measured with magnetic resonance and free surfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dopamine syntheses capacity in striatum (measured with F-DOPA using Positron emission tomography)</measure>
    <time_frame>Baseline and 6 weeks follow up</time_frame>
    <description>Dopamine measured with F-DOPA using Positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reward system activation in striatum (measured with functional magnetic resonance imaging)</measure>
    <time_frame>Baseline and 6 weeks follow up</time_frame>
    <description>Reward activity is measured with functional magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognition (measured with BACS (Brief Assessment of Cognition in Schizophrenia) and CANTAB (Cambridge Neuropsychological Test Automated Battery)</measure>
    <time_frame>Baseline, 6 weeks, 6 months &amp; 2 years</time_frame>
    <description>Neurocognition is measured with BACS (Brief Assessment of Cognition in Schizophrenia) and CANTAB (Cambridge Neuropsychological Test Automated Battery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychopathology (measured with PANSS (Positive and Negative Syndrome Scale)</measure>
    <time_frame>Baseline, 6 weeks, 6 months &amp; 2 years</time_frame>
    <description>Psychopathology is measured with PANSS (Positive and Negative Syndrome Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prepulse inhibition of the startle reflex and reduced P50 suppression ( measured with event related EEG and EMG)</measure>
    <time_frame>Baseline, 6 weeks, 6 months &amp; 2 years</time_frame>
    <description>Disturbances in early information processing in form of impaired sensory filtering as measured with event related EEG and EMG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>antipsychotic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>individual doses of aripiprazole for all patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment for all healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>6 weeks of individual doses of aripiprazole</description>
    <arm_group_label>antipsychotic treatment</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Patients:&#xD;
&#xD;
          -  Fulfilling the diagnostic criteria of schizophrenia or schizoaffective disorder&#xD;
             according to ICD-10 (International Classification of Diseases version 10) or DSM-IV/V&#xD;
             (Diagnostic and Statistical Manual version 4 /5)&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  Never treated with antipsychotic compounds or central nervous system (CNS) stimulants&#xD;
&#xD;
          -  Legally competent&#xD;
&#xD;
        Inclusion criteria controls:&#xD;
&#xD;
          -  Matching patients on age (+/- 2 years), sex and parental socioeconomic status&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  No psychiatric or physical disease&#xD;
&#xD;
        Exclusion Criteria patients:&#xD;
&#xD;
          -  Substance abuse on a daily basis during the last 3 month or patients fulfilling the&#xD;
             criteria of ongoing substance abuse due to ICD-10/DSM-IV/V&#xD;
&#xD;
          -  Treatment with antidepressant during the last 30 days&#xD;
&#xD;
          -  Head injury with more than 5 minutes of unconsciousness&#xD;
&#xD;
          -  Patients involuntarily admitted or treated&#xD;
&#xD;
          -  Components of metal implanted by operation&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe physical illness&#xD;
&#xD;
        Exclusion criteria controls&#xD;
&#xD;
          -  First degree relatives with psychiatric disease&#xD;
&#xD;
          -  Substance abuse during the last 3 month or positive screening of drugs in urine-sample&#xD;
&#xD;
          -  Head injury with more than 5 minutes of unconsciousness&#xD;
&#xD;
          -  Components of metal implanted by operation&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe physical illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte Glenthøj, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Capital Mental Health Services, Center for Neuropsykiatrisk Skizofreniforskning, CNSR &amp; Lundbeck Foundation Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Centre Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.psykiatri-regionh.dk/cinsr/Pages/default.aspx</url>
    <description>additional information</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Birte Glenthoj</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>glutamate</keyword>
  <keyword>dopamine</keyword>
  <keyword>cognition</keyword>
  <keyword>cortical thickness</keyword>
  <keyword>ppi</keyword>
  <keyword>p50</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

